VC-Backed Biotech IPOs: Valuations And Virtuous Cycles
8/4/2014 6:36:23 AM
As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets. 2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000. Last week was the busiest single week – with eight IPOs – since February 2000. Over 120 life science companies have gone public since the beginning of last year. This staggering volume of deals has brought nearly $10B of public equity financing to emerging life science players, at attractive prices, which serves as much-needed growth capital to advance their pipelines.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by